---
figid: PMC2895543__cvq13901
figtitle: Simplified scheme of pro-inflammatory signal transduction pathways leading
  to eNOS activation and endothelial hyperpermeability
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC2895543
filename: cvq13901.jpg
figlink: /pmc/articles/PMC2895543/figure/CVQ139F1/
number: F1
caption: Simplified scheme of pro-inflammatory signal transduction pathways leading
  to eNOS activation and endothelial hyperpermeability. Binding of pro-inflammatory
  agonists to their receptors activates a myriad of intracellular second messengers,
  leading to release of calcium from intracellular stores, PKC activation, Akt/PKB
  activation, and ERK-1/2 activation. The overall result is a functional state favouring
  changes in phosphorylation state of eNOS and elevated production of NO and increased
  permeability of the microvascular barrier. Several elements of the overall signalling
  paradigm remain elusive, such as the downstream effectors linking eNOS-derived NO
  to changes in the cytoskeleton and intercellular junctions that produce the hyperpermeable
  state, the precise role of the balance between cGMP and cAMP [via phosphodiesterases
  (PDE)] in permeability regulation. The mechanisms involved in the restoration of
  basal permeability and/or promotion of enhanced barrier integrity are represented
  by the Epac/Rap1 pathway.
papertitle: The NO cascade, eNOS location, and microvascular permeability.
reftext: Walter N. Dur√°n, et al. Cardiovasc Res. 2010 Jul 15;87(2):254-261.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9627748
figid_alias: PMC2895543__F1
figtype: Figure
redirect_from: /figures/PMC2895543__F1
ndex: 6ee67850-dec6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2895543__cvq13901.html
  '@type': Dataset
  description: Simplified scheme of pro-inflammatory signal transduction pathways
    leading to eNOS activation and endothelial hyperpermeability. Binding of pro-inflammatory
    agonists to their receptors activates a myriad of intracellular second messengers,
    leading to release of calcium from intracellular stores, PKC activation, Akt/PKB
    activation, and ERK-1/2 activation. The overall result is a functional state favouring
    changes in phosphorylation state of eNOS and elevated production of NO and increased
    permeability of the microvascular barrier. Several elements of the overall signalling
    paradigm remain elusive, such as the downstream effectors linking eNOS-derived
    NO to changes in the cytoskeleton and intercellular junctions that produce the
    hyperpermeable state, the precise role of the balance between cGMP and cAMP [via
    phosphodiesterases (PDE)] in permeability regulation. The mechanisms involved
    in the restoration of basal permeability and/or promotion of enhanced barrier
    integrity are represented by the Epac/Rap1 pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ca
  - Epac
  - Pld
  - norpA
  - sl
  - Plc21C
  - drk
  - Sos
  - ras
  - Ras64B
  - Ras85D
  - Rap1
  - Pa
  - Raf
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - dnc
  - Gycalpha99B
  - Dsor1
  - Dg
  - AP-1gamma
  - Mtk
  - Akt
  - rl
  - Strn-Mlck
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - ena
  - Act5C
  - Act42A
  - Act57B
  - Act79B
  - Act88F
  - Act87E
  - p38b
  - p38a
  - p38c
  - Cam
  - CaMKII
  - RAPGEF3
  - RAPGEF4
  - GPLD1
  - PLD1
  - PLD2
  - PLD3
  - PLD4
  - PLD5
  - PLD6
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - RAP1A
  - RABGEF1
  - TERF2IP
  - RAP1B
  - RAF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTG1
  - ALDH7A1
  - PDE2A
  - PDE9A
  - PDE10A
  - PDE11A
  - PDE1A
  - PDE1B
  - PDE1C
  - PDE3A
  - PDE3B
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - PDE6A
  - PDE6B
  - PDE6C
  - PDE7A
  - PDE7B
  - PDE8A
  - PDE8B
  - SGCB
  - GUCY1A2
  - GUCY1A1
  - GUCY1B1
  - GUCY1B2
  - MAP2K1
  - MAP2K2
  - MAP2K7
  - AKT1
  - PTK2B
  - AKT2
  - AKT3
  - MAPK3
  - MYLK
  - MYLK2
  - MYLK3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - VASP
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - NOS3
  - ENO4
  - CALM1
  - CALM2
  - CALM3
  - KRIT1
  - CAMKMT
  - ARHGEF12
  - Arg
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
---
